Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for stavudine (compound)


PubChem
Name: Stavudine
PubChem Compound ID: 10775595
Description: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
Molecular formula: C10H12N2O4
Molecular weight: 226.206 g/mol
DrugBank
Identification
Name: Stavudine
Name (isomeric): DB00649
Drug Type: small molecule
Description: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.
Synonyms:
Stavudine [Usan:Ban:Inn]; 2',3'-Didehydro-3'-deoxythimidine; STV; Stavudinum [INN-Latin]; Estavudina [INN-Spanish]; Sanilvudine; 3'-Deoxy-2'-thymidinene
Brand: Zerut XR, Zerit, Zerit XR
Category: Antimetabolites, Anti-HIV Agents, Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, Reverse Transcriptase Inhibitors
CAS number: 3056-17-5
Pharmacology
Indication: For the treatment of human immunovirus (HIV) infections.
Pharmacology:
Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack ...
show more »
Mechanism of Action: Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.
Absorption: Following oral administration, stavudine is rapidly absorbed (bioavailability is 68-104%).
Protein binding: Negligible
Biotransformation: Phosphorylated intracellularly to stavudine triphosphate, the active substrate for HIV-reverse transcriptase.
Half Life: 0.8-1.5 hours (in adults)
Clearance: Renal cl=272 mL/min [Healthy subjects receiving 80 mg PO] 594 +/- 164 mL/min [HIV-infected adult and pediatric patients following 1-hour IV infusion] 9.75 +/- 3.76 mL/min/kg [HIV- Exposed or -Infected Pediatric Patients(Age 5 weeks – 15 years) following 1-hour IV infusion]
Toxicity: Side effects include peripheral neuropathy tingling, burning, numbness, or pain in the hands or feet), fatal lactic acidosis has been reported in patients treated with stavudine (ZERIT) in combination with other antiretroviral agents, severe liver enlargement, inflammation (pain and swelling) of the liver, and liver failure.
Affected organisms: Human Immunodeficiency Virus
Interactions
Drug interaction:
ZidovudineZidovudine may decrease the efficacy of stavudine. Concomitant therapy should be avoided.

Targets


Transporters